Search

You searched for "conference"

783 results found
The Journal of Urology cover image.

Preoperative testosterone for hypospadias

5 September 2022 | | URO - Paediatrics
Hypospadias affects around 1 in 400 boys. Glans width (GW) of <14mm has been shown to be an independent risk factor for urethroplasty complications following hypospadias repair. Testosterone (T) administration in prepubertal males increases both penile length and circumference. Its...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | URO - Urologic Oncology
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

Outcomes of sarcomatoid differentiation in urothelial carcinoma

5 December 2022 | | URO - Urologic Oncology
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...
BJUI journal cover image.

How can we reduce morbidity after RARC with intracorporeal neobladder?

2 May 2025 | | URO - Functional / Reconstructive Urology
Robot-assisted radical cystectomy (RARC) is a complex procedure with high postoperative morbidity, especially when combined with neobladder reconstruction, which has a higher complication rate compared to other urinary diversions. To minimise these complications, it is crucial to understand their nature...
European Urology journal front cover.

Management dilemma for very high-risk non–muscle-invasive bladder cancer

4 November 2025 | | URO - Urologic Oncology
The European Association of Urology (EAU) guidelines recommend upfront radical cystectomy (RC) for very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC). However, real-world adoption is limited, as most patients are reluctant to undergo immediate bladder removal. The EAU 2021 risk model...

Wit, wine, whisky and wisdom – Prestonfield’s Burns Supper returns for 2026 in aid of Prostate Scotland

20 November 2025
Tickets are now on sale for Prestonfield’s annual Burns Supper, taking place on Thursday 22 January 2026 at the spectacular Prestonfield House in Edinburgh. This enchanting evening promises an opulent blend of wit, wine, whisky and wisdom, all in support...

Bladder cancer: where are we with intravesical therapies?

1 July 2016 | | URO - Urologic Oncology
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

The Bladder & Bowel UK Symposium North West 2025

20 March 2025
The Bladder & Bowel UK Symposium provides healthcare professionals with an excellent opportunity to receive relevant education from national speakers. The event includes a brand new programme of inspirational lectures, multi-disciplinary discussions and case studies to influence best practices, together with an extensive exhibition including company representatives and charitable services.

Ketamine uropathy – an update

29 January 2020 | | URO - Functional / Reconstructive Urology
The first two case series that documented the association between urinary tract damage and recreational ketamine use were published 12 years ago [1,2]. Since then ketamine has maintained a controversial profile as an essential medication of expanding utility but with...

Introducing Caress Flow, a painless, effective, and affordable treatment for intimate health

14 November 2024 | Company Profiles, Research & Development
Caress Flow, a groundbreaking treatment that promises to transform the management of vaginal pathologies, is now available in the UK. The innovative therapy offers a holistic, painless solution to a range of vaginal symptoms, with clinical evidence demonstrating significant benefits,...

IBSA UK&I assumes direct commercial responsibility for ialuril® in the UK and Ireland

9 April 2026 | Company Profiles, Contracts & Distributors
Transition supports continuity of supply and aligns ialuril® with IBSA’s expanding UK uro-gynaecology portfolio. Watford, UK – IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces that it will assume direct responsibility for the commercialisation and distribution...

Lasers in benign prostatic hyperplasia

1 January 2014 | | URO - Functional / Reconstructive Urology, URO - Technology
Clinical benign prostatic hyperplasia (BPH) impacts on the quality of life of many men. It is intimately related to ageing, but exact calculations of its prevalence remain difficult since an accurate clinical definition still eludes us. Histological BPH has been...